71 related articles for article (PubMed ID: 33390325)
21. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S; La Verde N; Rota S; Casazza G; Montrasio C; Cheli S; Cona MS; Dalu D; Fasola C; Ferrario S; Filipazzi V; Gambaro A; Tosca N; Clementi E
Pharmacogenomics J; 2021 Aug; 21(4):491-497. PubMed ID: 33649523
[TBL] [Abstract][Full Text] [Related]
22. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
[TBL] [Abstract][Full Text] [Related]
23. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
[TBL] [Abstract][Full Text] [Related]
24. Wipe-sampling procedure optimisation for the determination of 23 antineoplastic drugs used in the hospital pharmacy.
Guichard N; Boccard J; Rudaz S; Bonnabry P; Fleury Souverain S
Eur J Hosp Pharm; 2021 Mar; 28(2):94-99. PubMed ID: 33608437
[TBL] [Abstract][Full Text] [Related]
25. HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells.
Yoo J; Jeon YH; Lee DH; Kim GW; Lee SW; Kim SY; Park J; Kwon SH
Oncol Lett; 2021 Mar; 21(3):201. PubMed ID: 33574940
[TBL] [Abstract][Full Text] [Related]
26. Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer.
Kanai O; Ito T; Saito Z; Yamamoto Y; Fujita K; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
Thorac Cancer; 2021 Mar; 12(6):949-957. PubMed ID: 33559253
[TBL] [Abstract][Full Text] [Related]
27. Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone.
Ullah R; Ali G; Subhan F; Naveed M; Khan A; Khan J; Halim SA; Ahmad N; Zakiullah ; Al-Harrasi A
Neurochem Int; 2021 Mar; 144():104981. PubMed ID: 33549629
[TBL] [Abstract][Full Text] [Related]
28. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
29. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Rizzo A; Ricci AD; Brandi G
Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
[No Abstract] [Full Text] [Related]
30. A Multicenter Global Registry of Paclitaxel Drug-Coated Balloon in Dysfunctional Arteriovenous Fistulae and Grafts: 6-Month Results.
Karnabatidis D; Kitrou PM; Ponce P; Chong TT; Pietura R; Pegis JD; Ko PJ; Lin CH;
J Vasc Interv Radiol; 2021 Mar; 32(3):360-368.e2. PubMed ID: 33495064
[TBL] [Abstract][Full Text] [Related]
31. Cytosolic aromatic aldehyde dehydrogenase provides benzoic acid for xanthone biosynthesis in Hypericum.
Singh P; Kaufholdt D; Awadalah M; Hänsch R; Beerhues L; Gaid M
Plant Physiol Biochem; 2021 Mar; 160():82-93. PubMed ID: 33482582
[TBL] [Abstract][Full Text] [Related]
32. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.
van den Pol AN; Zhang X; Lima E; Pitruzzello M; Albayrak N; Alvero A; Davis JN; Mor G
Virology; 2021 Mar; 555():44-55. PubMed ID: 33453650
[TBL] [Abstract][Full Text] [Related]
33. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
34. Physcion Induces Hemolysis and Premature Phosphatidylserine Externalization in Human Erythrocytes.
Akiel M; Alsughayyir J; Basudan AM; Alamri HS; Dera A; Barhoumi T; Al Subayyil AM; Basmaeil YS; Aldakheel FM; Alakeel R; Ghneim HK; Al-Sheikh YA; Alraey Y; Asiri S; Alfhili MA
Biol Pharm Bull; 2021 Mar; 44(3):372-378. PubMed ID: 33431739
[TBL] [Abstract][Full Text] [Related]
35. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Park K; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
Gynecol Oncol; 2021 Mar; 160(3):660-668. PubMed ID: 33423806
[TBL] [Abstract][Full Text] [Related]
36. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
37. Complete but transient clinical remission of vulvar Paget's disease with paclitaxel and trastuzumab.
Isnard C; Plantier F; Thériaut M; Avril MF; Moyal-Barracco M
Ann Dermatol Venereol; 2021 Mar; 148(1):47-48. PubMed ID: 33422298
[No Abstract] [Full Text] [Related]
38. Cell growth analysis and nucleotide excision repair modulation in breast cancer cells submitted to a protocol using doxorubicin and paclitaxel.
Busatto FF; Viero VP; Schaefer BT; Saffi J
Life Sci; 2021 Mar; 268():118990. PubMed ID: 33412214
[TBL] [Abstract][Full Text] [Related]
39. Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers.
Gonzales J; Hernández-Gil J; Wilson TC; Adilbay D; Cornejo M; Demétrio de Souza Franca P; Guru N; Schroeder CI; King GF; Lewis JS; Reiner T
Mol Pharm; 2021 Mar; 18(3):940-951. PubMed ID: 33404254
[TBL] [Abstract][Full Text] [Related]
40. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
